TRA2A is highly expressed in breast cancer, glioma, and liver cancer, while PYCR2 is regarded as a prognostic biomarker in the HBV-related HCC (Tieju Liu et al., 2017; Tan et al., 2018; Gao et al., 2019). This evidence concerns the gene PYCR2 and central nervous system cancer.